The Post-Market Drug Evaluation (PMDE) Advisory Committee is a multi-disciplinary group that provides credible, strategic PMDE advice and expertise to CADTH on queries, strategic initiatives, and key priority areas.
The membership of the Advisory Committee will include decision-makers, applied researchers, methodologists and/or analysts, patients and/or caregivers, clinicians, industry representatives, PMDE network members, and PMDE Operations Centre staff. Its size and composition will reflect the program’s commitment to be operationally responsive to changes in the pharmaceutical environment, and to position CADTH to enable future-ready health care by responding to the evidence needs of decision-makers.
PMDE Advisory Committee reports to the CADTH president and CEO. Members must abide by the CADTH Conflict of Interest Guidelines as well as the CADTH Code of Conduct.
If you are interested in being a part of the inaugural PMDE Advisory Committee, please visit the 2022 nominations web page for additional information.